Objective of the Circular
- Formal adoption of the ICH Harmonised Tripartite Guideline Q5C.
- Establishes a regulatory requirement for conducting stability studies on biotechnological/biological products.
- Ensures alignment with international standards to enhance product safety and quality.
Scope and Definitions
- Applies to manufacturers, traders, exporters, importers, and wholesalers of biotechnological/biological products including vaccines.
- Biological Products: Includes attenuated/inactivated viruses or bacteria, toxoids, hyperimmune serums, components for diagnosis/prevention/treatment derived from living matter.
- Also includes products prepared to develop immunity, prepared from human blood/plasma or manufactured via biotechnology, with complex molecular composition.
- Excludes low molecular weight antibiotics and purified chemical substances like steroids and alkaloids.
- Biotechnological Products: Any product prepared through genetic engineering or newer biotechnology techniques, all of which are classified under biological products.
Implementation Details
- Stability testing must comply with the ICH Q5C guideline covering batch selection, stability profile, storage, testing frequency, specifications, and product labeling.
- All supplements and revisions to the ICH Q5C guideline shall be automatically adopted.
- The guideline will be accessible publicly via the FDA website.
Transitory Provisions
- The revised stability requirements only apply to new incoming applications.
- Pending applications and existing compliance cases are exempt from this Circular.
Repealing and Separability Clauses
- Previous circulars and memoranda inconsistent with this Circular are repealed or revoked.
- If any provision is invalidated, the remainder of the Circular remains effective and enforceable.
Effectivity
- The Circular took effect immediately on November 11, 2013.